Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reaffirmed at Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reissued by research analysts at Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $300.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s target price indicates a potential upside of 18.30% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. HC Wainwright increased their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Sanford C. Bernstein decreased their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $310.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $304.74.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $253.60 on Friday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a market capitalization of $32.83 billion, a PE ratio of -116.87 and a beta of 0.39. The company has a fifty day moving average of $256.25 and a two-hundred day moving average of $259.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 over the last ninety days. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ALNY. Larson Financial Group LLC boosted its position in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the period. Park Square Financial Group LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $28,000. R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $35,000. Finally, Colonial Trust Co SC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $35,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.